Xeris Biopharma Holdings, Inc. - Common Stock (XERS)
4.8200
+0.2600 (5.70%)
Xeris Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for patients with chronic diseases and conditions
Utilizing its proprietary technology platforms, the company aims to enhance the delivery of injectable medications, creating formulations that are designed to be more convenient and effective for patients. Xeris is dedicated to addressing unmet medical needs by bringing forward products that can improve treatment experiences and outcomes for individuals with conditions such as diabetes and other specialty therapy needs.

The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies.
Via Talk Markets · March 11, 2025

The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.
Via Stocktwits · March 6, 2025

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via Chartmill · March 6, 2025

Via Benzinga · November 11, 2024

Via Benzinga · August 14, 2024

Xeris Biopharma Holdings Inc (NASDAQXERS) shares are trading higher by around 9% after the
Via Benzinga · October 16, 2023

Via Benzinga · August 13, 2024

XERS stock results show that Xeris Biopharma Holdings beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024

Via Benzinga · May 13, 2024

XERS stock results show that Xeris Biopharma Holdings missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024

Xeris Biopharma shares are up Monday after the company announced an exclusive worldwide collaboration and license agreement with Beta Bionics. Xeris said it will work with Beta Bionics to develop and release a glucagon product that will utilize the company's XeriSol technology and Beta Bionic's pump systems.
Via Benzinga · May 6, 2024

XERS stock results show that Xeris Biopharma Holdings met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 6, 2024

Shares of WD-40 Company (NASDAQWDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results.
Via Benzinga · January 10, 2024

Chewy stock is falling on Wednesday after it was announced that Morgan Stanley is handling a block sale of CHWY shares.
Via InvestorPlace · January 10, 2024

Companies Reporting Before The Bell • CTS (NYSECTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.
Via Benzinga · March 6, 2024

Xeris Biopharma stock is rising higher on Wednesday as investors in XERS shares react to a new exclusive worldwide license agreement.
Via InvestorPlace · January 10, 2024

Small cap stocks are anticipated to rise by as much as 50% in 2024 as investors look for growth in new areas of the market.
Via InvestorPlace · January 8, 2024

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSELW) rose during Thursday’s session following better-than-expected quarterly results.
Via Benzinga · January 4, 2024

Via Benzinga · August 28, 2023

Companies Reporting Before The Bell • Indivior (NASDAQINDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
Via Benzinga · November 9, 2023

The Dow Jones closed lower by around 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · August 10, 2023